Resistance to the HER-2 targeting drug trastuzumab is observed clinically, but the lack of suitable experimental models hampers studies of resistance mechanisms. We characterized a HER-2 positive carcinoma cell line (JIMT-1) derived from a 62-year-old breast cancer patient, clinically resistant to trastuzumab. m-FISH revealed a complex hyperdiploid karyotype with numerous marker chromosomes and unbalanced translocations. CGH revealed numerous regions of copy number aberration (CNA). Further analysis by a-CGH identified 27 regions of CNA (16 amplified, 11 deleted). 38% of the genes in the amplified regions were overexpressed, compared to only 9% in regions of normal copy number ratios (CNR). Accordingly, 26% of the genes in the deleted regions were underexpressed, compared to 10% in regions of normal CNR. Most amplified and overexpressed genes were located on chromosome 1 as well as on 8q, 12q14.1, 17q11-q21, and 20q13. In 17q11-q21 we identified two separate amplicons, the HER-2 amplicon, and a previously unreported amplicon at 17q21.31. Several aberrant genes are implicated in cancer development (e.g. JUN, CDK4 and SLUG protooncogenes, and the drug/hormone metabolizing genes GSTM1 and CYP24). We conclude that cytogenetic and expression profiling of JIMT-1 revealed several new features that needs further characterization, which may shed light on the trastuzumab resistance.
Introduction
Breast cancer arises due to a series of recurrent alterations in the genome of the normal epithelial cell. The importance of these gene and chromosome alterations in the development and progression of solid tumors have been extensively characterized in the literature. For example, amplification of the HER-2 oncogene and overexpression of its concomitant protein is associated with an increased risk of relapse and death. According to some studies it is also associated with an altered response to hormonal and cytotoxic therapies [1] . The HER-2 oncogene is amplified and overexpressed in ~20% of all human breast cancers [1] . The gene encodes a 185-kD transmembrane tyrosine kinase receptor. The finding that monoclonal antibodies against this receptor can inhibit growth in cancer cells that overexpress the HER-2 receptor on the cell surface is considered a major discovery in breast cancer therapy [2] . This led to the development of a humanized monoclonal HER-2 antibody, trastuzumab, which has a profound growth-inhibitory effect in metastatic breast cancer [3, 4] .
Trastuzumab (Herceptin®) is currently used widely as treatment for metastatic breast cancer.
It is effective alone, and especially in combination with taxanes or vinorelbine, in 60-80% of HER-2 positive tumors [5] . However, for the remaining patients Herceptin® has no beneficial effect, even though the HER-2 gene is amplified and the protein is overexpressed, in the primary tumor as well as in the metastasis [6] . The development of primary resistance to trastuzumab must therefore be influenced by other, currently unknown factors. Identification of molecular markers of potential resistance mechanisms could be useful to distinguish potentially non-responding patients even before the start of Herceptin® treatment. New drugs that might be given alone or in combination with trastuzumab in order to circumvent the resistance, may potentially be developed based on the knowledge of such resistance mechanisms.
At present, the lack of suitable experimental model systems, impede studies of trastuzumab resistance. Here we characterize a novel cell line derived from a breast cancer patient with a Herceptin® resistant tumor by multicolor fluorescent in situ hybridization (m-FISH), comparative genomic hybridization (CGH), microarray based CGH (a-CGH), and gene expression pattern by c-DNA microarray.
Materials and Methods
The JIMT-1 cell line and xenograft
The clinical history of the patient from which the cell line and xenografts were derived has been described elsewhere [7] . Briefly, a 62 year old woman, initially diagnosed with a grade III invasive ductal breast cancer (stage T2N1M0) underwent surgery with radical mastectomy and axillary lymph node evacuation. Metastases were found in 1 of 12 lymph nodes examined. The patient was recruited to a randomized adjuvant trastuzumab therapy trial, where she received a combination of trastuzumab (4mg/kg initiation dose, continued with 2mg/kg) and vinorelbine (25mg/m 2 ), followed by three courses of standard dose CEF (cyclophosphamide 600mg/m 2 , epirubicin 60mg/m 2 , 5-fluorouracil 600mg/m 2 , three weekly i.v.) and post-operative radiation therapy (50Gy). Only two weeks after the completion of radio therapy the patient presented an ipsilateral pleural effusion containing carcinoma cells.
The disease progressed although therapy for distant metastatic disease was initiated, and a palliative pleural puncture was clinically necessary. The material for cell culture was obtained from this second aspirate. The patient died twelve weeks after first diagnosis of distant metastasis. Approval to use cancer cells for culture and experimental studies was obtained from the patient and the local ethical committee prior to the study. The resulting cell line, designated JIMT-1, showed continuous growth, and can recover from cryopreservation (FBS 90%/DMSO 10%). In order to test xenograft tumor formation, approximately 3-5 million trypsinized JIMT-1 cells in PBS were injected subcutaneously into nude mice.
Genetic and phenotypic characterization
The primary breast tumor from the patient and formalin-fixed paraffin-embedded JIMT-1 xenografts has been studied by immunohistochemistry (IHC) for estrogen receptor (ER), progesterone receptor (PgR), HER-2, Ki67, pan-cytokeratin, and TP53 previously [7] .
Fluorescence and chromogenic in situ hybridization (FISH and CISH, respectively) were carried out to study the amplification of known breast cancer oncogenes. The hybridization protocols and the digoxigenin-labeled genomic BAC and PAC probes for HER-2, EGFR, TOPOIIα, c-MYC, CCND1, and 20q13 have been characterized in our previous studies [6, 8, 9] . Denaturating high performance liquid chromatography (DHPLC) was carried out to detect mutations in the p53 gene (exons 5-9) as described elsewhere [10] . DNA flow cytometry was carried out according to an established protocol [11] .
Cytogenetic analyses
The JIMT-1 cells were harvested (trypsinized) after exposure to colcemid for 4 hours, followed by a hypotonic shock in 0.05M KCl, and fixation in methanol/acetic acid. m-FISH was carried out according to the manufacturer's instructions (X-Cyte kit, MetaSystems Gmbh, Altlusheim, Germany) [12] . CGH was performed as previously described [12] [13] [14] . DNA genotyping analysis to confirm the identity of JIMT-1 cells was based on the PowerPlex [15] . Background corrections of Cy3 and Cy5 intensities were calculated using the median feature and median local background intensities provided in the quantified data matrix. Within arrays, intensity ratios for individual probes were calculated as background corrected intensity of test sample divided by background corrected intensity of reference sample. Probes with a signal-to-noise ratio (SNR) < 2 in either of the two channels, or with a spot diameter < 40 nm were excluded from further analysis and regarded as missing values. Arrays were normalized using a BASE implementation of the pin-based LOWESS algorithm [16, 17] . The mean value from the two corresponding dye-swap experiments was used for further analysis. Mapping information regarding clone locations and cytogenetic banding were retrieved from the UCSC genome browser III (July 2003 freeze) and UniGene build 160 at NCBI IV .
Identification of regions of amplification or deletion
Regions of amplifications and deletions in the a-CGH data were defined as a ratio >2.0 or <0.5, respectively, in at least three adjacent c-DNA clones. Amplified regions were then extended to include neighboring genes with a ratio >1.5 [18] . With technical flaws in consideration we also extended the regions, allowing one or two genes with a ratio below 1.5 if the next gene had a ratio >1.5, or not more than three genes below 1.5 if the next gene had a ratio >2.0. In the same way we extended deleted regions to include neighboring genes with a ratio <0.67 (1/1.5), allowing not more than two genes with a ratio above 0.67 if the next gene had a ratio <0.67, or not more than three genes above 0.67 if the next gene had a ratio <0.5.
Establishment of statistical correlation between a-CGH and expression analysis
We employed a leave-one-out method based on Spearman correlation, to produce a list of genes contributing the most to the correlation between a-CGH and expression ratios. For each of the genes we calculated the difference between the Spearman correlation coefficient with and without the gene, sorted the differences, and excluded the one contributing most to the positive correlation. The excluded gene was ranked as number one. By repeating this procedure for the remaining set of genes we found the second one on the list, etc. 
Genetic and phenotypic characterization
In order to reveal the susceptibility to trastuzumab therapy, the primary tumor of the patient was screened for amplification of the HER-2 gene and overexpression of its concomitant protein by CISH and IHC, respectively. The tumor displayed a 3+ overexpression by IHC, and was shown to be amplified by CISH. Gene amplification (approximately 20-30 copies/cell) was found by FISH in the pleural metastatic cells and in the JIMT-1 cells after 10 passages. Gene amplification of HER-2 was found also in the xenograft tumors by CISH [7] .
IHC of the primary breast tumor and a JIMT-1 xenograft showed no staining for ER and PgR, but strong immunopositivity for p53. Abundant Ki-67 labeling evidenced a high cell proliferation rate. The epithelial origin of the JIMT-1 cells was confirmed by a strongly positive pan-cytokeratin immunostaining.
FISH analysis of genes commonly amplified in breast cancer (other than HER-2)
revealed amplification of 20q13, whereas no amplification was found in EGFR, TOPOIIα, c-MYC, and CCND1. A point mutation was found in the p53 gene (exon 7) by DHPLC analysis.
The results are summarized in Table 1 .
Cytogenetic characterization by m-FISH and CGH.
Cytogenetic analysis with m-FISH revealed a complex hyperdiploid karyotype with numerous chromosome aberrations. On average, there were 52-57 chromosomes, which is in line with the DNA flow cytometry DNA-index of 1.35. Several complex translocations occurred, implicating chromosomes 1, 8, 12, and 17 as being frequently involved in genetic recombination ( Fig. 1 ; Table 2 ).
Chromosomal CGH of the JIMT-1 cell line and xenograft revealed copy number gains at 1p31-p32, 1q23-q25, 1q41-q42, 5p11-p13, 6p, 8q, 9q22-qter, 11p11-p15.2, 12q13-q14, 17q12-q22, 18p11.21-pter, 20q, and losses at 1p11-p13, 4p11-p15.3, 4q33-qter, 5q14, 7q21-q32, 9p13-pter, 18q, and Xp (Table 3 ). The CGH findings matched well with those observed in the untreated primary tumor of the patient. The copy number imbalances were the same, except for the losses at 7q and Xp, which were not found in the primary tumor.
Cytogenetic characterization by a-CGH
The correlation between JIMT-1 cell line and xenograft a-CGH was very high (data not shown). a-CGH mapping identified 16 independent amplification sites, and 11 independent sites of deletion, which are all listed in Table 3 . Amplicons ranged in size from 0.52Mb up to 28.8Mb, and deleted regions ranged from 1.92Mb up to 48.51Mb. Several previously undescribed patterns of copy number aberrations (CNAs) were detected, including five individual amplicons and one deletion on chromosome 1, amplifications on 12q14.1 and 17q21.31, the latter being located at 3.5Mb distance from the HER-2 region.
Comparison of chromosomal CGH and a-CGH
The concordance between CGH and a-CGH was generally very high. As expected, several large amplifications found by chromosomal CGH was explained by, often more than one, narrow, but high-level amplification found by a-CGH. In particular the aberrations on chromosomes 1, 8, 11, 12, and 17 revealed more detailed aberration patterns by a-CGH ( Fig.   2 ; Table 3 ).
Correlation between a-CGH copy number aberrations and gene expression
When comparing the gene expression analysis data to that of a-CGH, a clear correlation between CNAs and the level of gene expression was found. A large fraction (38%) of the genes in the amplified regions were also overexpressed (i.e. belonged to the upper 10% of expression ratios), compared to only 9% in regions of normal copy number ratios (p<<0.001).
Accordingly, 26% of the deleted regions were also underexpressed (i.e. belonged to the lower 10% expression ratios), compared to 10% in regions of normal copy number ratios (p<<0.001). Expression ratios for chromosomes 1, 8, 11, 12, and 20, correlating to CGH and a-CGH data, are shown in Fig. 2 , and the expression ratio of chromosome 17 in correlation to CGH and a-CGH data is shown in Fig. 3 . A second gene expression hybridization using RNA from a pool of HER-2 amplified, but trastuzumab sensitive, breast cancer cell lines revealed that the genes from the amplicon at 17q21.31 are overexpressed in JIMT-1 compared to trastuzumab sensitive breast cancer cell lines (Fig. 4) . When studying JIMT-1 by chromosomal CGH, an aberration pattern typical for that of an aggressive breast cancer was found [21] [22] [23] . A high number of CNAs is by itself a predictor of poor clinical outcome, and in particular the gains on 8q, 17q, and 20q have been shown to be connected to poor patient prognosis [13] . The CGH profiles of the primary tumor, JIMT-1 cell line, and its xenograft were identical in 17 of 19 CNAs found. The exceptions were the losses at 7q and Xp, which were not found in the primary tumor. This may reflect clonal selection during metastatic process in the patient or during cell culture.
Equally likely is that it is caused by the diluting effect of normal cell contamination in the paraffin block used for DNA extraction of the primary breast tumor of the patient. In general, the high resemblance of the CGH findings between the primary tumor and a cell line derived from its metastasis indicates the stability of the genotype.
The resolution of chromosomal CGH is limited, and is insufficient for in depth analysis of aberrant chromosomal regions. Microarray-based CGH provides a much higher resolution, allowing detection of rearrangements at the gene level. The concordance between CGH and a-CGH was generally high in the presented study. Several of the larger regions of amplification as detected by chromosomal CGH were found by a-CGH to contain often more than one, small amplicon with high-level amplification. Complex aberration patterns were seen on chromosome 1, and on segments 12q14.1 and 17q11.2-q21.
By using a-CGH in combination with m-RNA expression profiling it is possible to identify and characterize genes whose m-RNA expression is most significantly associated with amplification of the corresponding genomic template. We found a statistically significant correlation between CNA by a-CGH and expression level in amplified as well as deleted regions. This is clearly an indication that gene copy number is linked to expression level also in the case of lost genetic material, and that transcription from the remaining gene copy is not sufficient to compensate for the loss of the other allele.
A large number of the genes in these regions was also differentially expressed and have the potential to promote breast cancer progression. For example, the protooncogene JUN, located on 1p31-p32, is believed to encode the enhancer protein AP-1 that interacts directly with specific target DNA sequences to regulate gene expression, as well as the general transcription factor II B (TFIIB), located on 1p21-p22, that encodes a factor required for transcription initiation by RNA polymerase II. To our knowledge this gene has not previously been shown to undergo amplification in human cancers.
In the deleted region on chromosome subband 1p13.3, we found the GSTM1
(glutathione S-transferase M1) also to have a low level of expression. This enzyme detoxifies electrophilic compounds, including carcinogens, by conjugation with glutathione. Null mutations of this gene have been linked with an increase in a number of cancers, breast cancer being one [24] , likely due to an increased susceptibility to environmental toxins and carcinogens.
The small amplicon on 12q14.1 harbors the Cyclin-dependent kinase 4 gene (CDK4), which is amplified and overexpressed. CDK4 is involved in cell-cycle control where it drives cells from G1 into s-phase. CDK4 has previously been shown linked to highly proliferating sporadic breast cancer [25] . CNR for the xenograft has been added for comparison. 
